

INVITATION

Abivax Satellite Symposium
related to 8th ClinCom Workshop

Thursday, February 17, 2022
12:00 – 13:00

ABX464, a novel anti-inflammatory drug-candidate for the treatment of ulcerative colitis entering into phase 3 clinical testing

AGENDA

Chairman: Prof. Bruce Sands, M.D., M.S.

- | | |
|----------------------|--|
| 12:00 – 12:05 | Welcome and opening remarks |
| 12:05 – 12:20 | The continued need to develop novel drugs for ulcerative colitis
Prof. William Sandborn, M.D.
<i>University of California San Diego School of Medicine and
Co-Founder and Chief Medical Officer at Shoreline Biosciences,
CA, USA</i> |
| 12:20 – 12:35 | ABX464 novel mechanism of action: Upregulation of the anti-inflammatory microRNA miR-124
Didier Scherrer, Ph.D.
<i>Abivax, France</i> |
| 12:35 – 12:50 | Safety and efficacy of ABX464 in ulcerative colitis and the implementation of a global phase 3 program
Prof. Bruce Sands, M.D., M.S.
<i>Dr. Burrill B. Crohn Professor of Medicine at the Icahn School of
Medicine at Mount Sinai, New York City, NY, USA</i> |
| 12:50 – 13:00 | Questions and answers |